Nuwellis Q4 revenue $2.3M (-9% YoY); net loss narrows to $1.5M from $7.9M

Nuwellis, Inc.

Q4 revenue $2.3M, down 9% YoY; consumables utilization +21%, critical care revenue +35%.
Gross margin 58.4% vs 54.4% YoY; includes $150K voluntary recall expense.
Operating loss $2.4M, improved from $3.6M; full-year cost reduction $5.9M (-26%).
Net loss attributable to common $1.5M ($0.44/share) vs $7.9M ($54.48/share) YoY.
Cash $5.1M, no debt; CMS payment for Aquadex increased 4x to $1,639 effective Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.